TY - JOUR T1 - <sup>18</sup>F-DCFPyL PET/CT in Metastatic Renal Cell Carcinoma JF - Journal of Nuclear Medicine Technology JO - J. Nucl. Med. Technol. SP - 282 LP - 285 DO - 10.2967/jnmt.121.262799 VL - 50 IS - 3 AU - Geoffrey M. Currie AU - Marko Trifunovic AU - Jui Liu AU - Sang Kim AU - Howard Gurney Y1 - 2022/09/01 UR - http://tech.snmjournals.org/content/50/3/282.abstract N2 - Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers. ER -